HeartFlow Raises 2026 Revenue Outlook
The cardiac imaging company lifted its full-year revenue and Plaque revenue forecasts after strong third-quarter growth.
Updated on Nov. 13, 2026 in Healthcare

HeartFlow raised its 2026 revenue outlook to $262 million to $264 million after third-quarter sales grew 57.4% from a year earlier to $72.9 million. The company also raised its Plaque revenue outlook to $36 million to $37 million.
Why it matters
The raised forecast reflects accelerating adoption of HeartFlow's Plaque product and continued utilization of its FFRCT technology in the growing market for coronary CT angiography. Strong U.S. growth and improving margins point to a business moving closer to sustained profitability.
HeartFlow reported third-quarter revenue of $72.9 million, up 57.4% from a year earlier, with a non-GAAP gross margin of 83.8% and a non-GAAP operating loss narrowed to $5 million. The company raised its 2026 gross-margin outlook to about 82.5%, though it has not yet shown the full-year operating profit its forecasts imply.
The players
HeartFlow
HeartFlow is a medical technology company that provides AI-driven cardiac imaging analysis tools used by physicians to assess coronary artery disease.
The details
HeartFlow said U.S. revenue increased 60% in the third quarter, its fastest growth in 11 quarters. The company credited accelerating Plaque adoption, continued FFRCT utilization, new account additions and growth in the coronary CT angiography market for the higher outlook.
Timeline
Third quarter 2026: Revenue reached $72.9 million and U.S. growth hit 60%.
Fourth quarter 2026: Plaque pricing is expected to be roughly flat sequentially.
Year-end 2026: About 1,300 Plaque-activated accounts are expected.
2027: The company expects more operating leverage.
Mid-2028: HeartFlow reiterated its target of cash flow profitability.
Healthcare Landscape
HeartFlow's growth tracks the expanding use of coronary CT angiography as a first-line test for coronary artery disease, with the company's FFRCT and Plaque tools adding analysis layers to that imaging. The raised outlook suggests the company is capturing a larger share of that growing diagnostic market rather than relying on market growth alone.
For patients, faster and more widely available cardiac imaging analysis can shape how quickly coronary artery disease is evaluated. Investors and industry watchers can track whether HeartFlow's margins and profitability targets hold as its account base grows toward the year-end goal.
The takeaway
Growth in the cardiac imaging market is increasingly being driven by analysis tools layered on top of standard scans. Watching whether companies like HeartFlow convert rising adoption into sustained profitability will show how durable that shift is.
Further reading
Explore more healthcare business news to see how medical technology companies are performing.





